Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SELECTA BIOSCIENCES, INC.

(SELB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Selecta Biosciences : Cyrus Biotechnology Collaborating to Create Engineered Therapeutic Proteins

09/08/2021 | 12:22pm EDT


ę MT Newswires 2021
All news about SELECTA BIOSCIENCES, INC.
10:21aSelecta Biosciences Partners With Ginkgo Bioworks to Advance Treatments For Orphan, Rar..
MT
08:03aSELECTA BIOSCIENCES INC : Other Events (form 8-K)
AQ
10/25SELECTA BIOSCIENCES INC : Entry into a Material Definitive Agreement, Termination of a Mat..
AQ
10/21SELECTA BIOSCIENCES : Working With Genovis to Advance IgG Protease in Gene Therapy, Autoim..
MT
10/21SELECTA BIOSCIENCES INC : Other Events (form 8-K)
AQ
10/21GENOVIS : announces exclusive license agreement with Selecta Bioscience to develop and pro..
AQ
10/21SELECTA BIOSCIENCES : and Genovis Enter Exclusive License Agreement to Advance Next-Genera..
AQ
10/21Genovis AB Announces Exclusive License Agreement with Selecta Bioscience to Develop and..
CI
10/20SELECTA BIOSCIENCES : to Participate in Jefferies Virtual Gene Therapy/Editing Summit
AQ
10/13SELECTA BIOSCIENCES : to Present New Data for the ImmTOR™ platform at the ESGCT 28th..
AQ
More news
Analyst Recommendations on SELECTA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 55,1 M - -
Net income 2021 -36,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,2x
Yield 2021 -
Capitalization 412 M 412 M -
Capi. / Sales 2021 7,47x
Capi. / Sales 2022 10,1x
Nbr of Employees 44
Free-Float 71,6%
Chart SELECTA BIOSCIENCES, INC.
Duration : Period :
Selecta Biosciences, Inc. Technical Analysis Chart | SELB | US8162121045 | MarketScreener
Technical analysis trends SELECTA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,58 $
Average target price 8,67 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
Carsten Brunn President, Chief Executive Officer & Director
Kevin Tan Chief Financial & Accounting Officer
Carrie Smith Cox Chairman
Lloyd Johnston COO, Senior Vice President-Research & Development
Takashi Kei Kishimoto Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
SELECTA BIOSCIENCES, INC.18.15%412
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.23.63%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992